Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Marko Škrtić(Ontario Institute for Cancer Research), David Z.I. Cherney(University Health Network), Uli C. Broedl(Boehringer Ingelheim (Germany)), Nima Soleymanlou(Boehringer Ingelheim (Canada)), Thomas Hach(Novartis (Switzerland)), Hans J. Woerle(Boehringer Ingelheim (Germany)), Maximilian von Eynatten(Nestlé (Switzerland)), Yuliya Lytvyn(University Health Network), Gary K. Yang(University of Toronto), Bruce A. Perkins(Sinai Health System), Melvin Silverman(University of Toronto), Odd Erik Johansen(Boehringer Ingelheim (Norway))
Cited by 162
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Adipokines and Insulin Resistance
|Molecular Medicine|2008|804
Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2011|692
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470